Not Yet Recruiting
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
NCT07469956
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, China